SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.

Atherosclerosis
Antonio GalloFrench REgistry of Familial hypERCHOLesterolemia (REFERCHOL) investigators

Abstract

Patients with heterozygous familial hypercholesterolemia (HeFH) present elevated cardiovascular (CV) risk. Current CV risk stratification algorithms developed for the general population are not adapted for heFH patients. It is therefore of singular importance to develop and validate CV prediction tools, which are dedicated to the HeFH population. Our first objective was to validate the Spanish SAFEHEART-risk equation (RE) in the French HeFH cohort (REFERCHOL), and the second to compare SAFEHEART-RE with the low-density-lipoprotein-cholesterol (LDL-C)-year-score for the prediction of CV events in the HeFH French population. We included HeFH (n = 1473) patients with a genetic or clinical diagnosis (DLCN score ≥8). Among them, 512 patients with a 5-year follow-up were included to validate the 5 year-CV-RE. A total of 152 events (10.3%) occurred in the entire population of 1473 patients during a mean follow-up of 3.9 years. Over the five-year follow-up, non-fatal CV events occurred in 103 patients (20.2%). Almost all the parameters used in the SAFEHEART-RE were confirmed as strong predictors of CV events in the REFERCHOL cohort. The C-statistic revealed a satisfactory performance of both the SAFEHEART-RE and LDL-C-year-scores in pr...Continue Reading

References

Jul 16, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Fernando CiveiraUNKNOWN Spanish Familial Hypercholesterolemia Group
Jan 24, 2008·Circulation·Ralph B D'AgostinoWilliam B Kannel
Aug 16, 2012·The Journal of Clinical Endocrinology and Metabolism·Marianne BennBørge G Nordestgaard
Aug 23, 2012·JAMA : the Journal of the American Medical Association·Hester M Den RuijterMichiel L Bots
Nov 7, 2013·Circulation Research·Dorothé M KustersBarbara A Hutten
Mar 19, 2014·Journal of the American College of Cardiology·Allan D SnidermanSergio Fazio
May 20, 2015·Annals of Internal Medicine·Gary S CollinsKarel G M Moons
Jun 2, 2016·The Lancet. Diabetes & Endocrinology·Raul D SantosUNKNOWN International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Sep 30, 2016·Journal of Clinical Lipidology·Sophie BéliardUNKNOWN French FH Registry group
May 1, 2017·Journal of Clinical Lipidology·Antonio GalloDavid Rosenbaum
Mar 3, 2018·Journal of the American College of Cardiology·Karen A HicksUNKNOWN Standardized Data Collection for Cardiovascular Trials Initiative (SCTI)
Nov 2, 2018·Current Opinion in Lipidology·Pedro MataLeopoldo Pérez de Isla
Mar 9, 2019·Journal of the American College of Cardiology·Katrina L EllisPedro Mata
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Oct 17, 2019·The New England Journal of Medicine·Ilse K LuirinkBarbara A Hutten

❮ Previous
Next ❯

Citations

Nov 17, 2020·The New England Journal of Medicine·Robert S RosensonDaniel Gaudet
May 8, 2021·Atherosclerosis·Christoph J BinderArnold von Eckardstein
May 21, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Hayato TadaMasa-Aki Kawashiri
Jul 19, 2021·JACC. Cardiovascular Imaging·Antonio GalloUNKNOWN REFERCHOL and SAFEHEART investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.